Evidence map›Paper›PMID 40143654›Full record

ArticleACS chemical neuroscience2025

Uncovering Amyloid-β Interactions: Gray versus White Matter.

Gabriel Cathoud, Mohtadin Hashemi, Yuri Lyubchenko, Pedro Simões

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gabriel CathoudCERES, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Pólo II, 3030-790 Coimbra, Portugal.ORCID 0000-0002-3450-7577
Mohtadin HashemiDepartment of Physics, Auburn University, Auburn, Alabama 36849-5318, United States.ORCID 0000-0003-2698-9761
Yuri LyubchenkoDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.ORCID 0000-0001-9721-8302
Pedro SimõesCERES, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Pólo II, 3030-790 Coimbra, Portugal.ORCID 0000-0002-5068-950X

Funding

Breakthrough Molecular Dynamics Research via an Anton2 SupercomputerR01GM116961 · NIGMS · CARNEGIE-MELLON UNIVERSITY · PI BLOOD, PHILIP D. · 2016 to 2023
$3.0M
Nanoscale assembly of amyloid oligomers at physiologically relevant conditionsR01GM148537 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI YURI L LYUBCHENKO · 2023 to 2026
$2.0M
NIGMS NIH HHS R01 GM116961NIGMS NIH HHS R01 GM148537
6 · The paper itself

Abstract

Alzheimer's disease is characterized by the accumulation of amyloid plaques in the brain. Recent studies suggest that amyloid-β (Aβ) peptides interact with cell membranes, potentially catalyzing plaque formation. However, the effect of varying cell membrane compositions on this catalytic process requires further investigation. Using molecular dynamics simulations, we demonstrate that a model gray matter membrane significantly influences the secondary structure of β-amyloid peptides. Notably, residues Asp1 and Glu22 play crucial roles in the membrane interaction. Glutamic acid at position 22, located in the middle of the peptide chain, appears to promote the formation of β-hairpin conformations, which are critical for aggregation. Additionally, our simulations reveal that the model white matter membrane allows a spontaneous insertion of segments of the peptide into the membrane, suggesting that membrane interaction not only alters the peptide structure but may also compromise membrane integrity. Our results show that the different membrane compositions in the brain may play different roles when interacting with β-amyloid peptides.

Indexed as

Amyloid beta-PeptidesGray MatterWhite MatterAlzheimer DiseaseCell MembraneHumansMolecular Dynamics SimulationProtein Structure, SecondaryAmyloid beta-PeptidesAlzheimer’s diseaseamyloid-βmembrane–peptide interactionmolecular dynamics

Identifiers

PMID40143654
PMCPMC12818754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.